Scarica l'app Stockscreener
1.44
3.36%
-0.05
Dopo l'orario di chiusura:
1.44
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMEA Giù?
Forum
Previsione
Precedente Chiudi:
$1.49
Aprire:
$1.45
Volume 24 ore:
542.98K
Relative Volume:
0.78
Capitalizzazione di mercato:
$54.10M
Reddito:
-
Utile/perdita netta:
$-144.01M
Rapporto P/E:
-0.3591
EPS:
-4.01
Flusso di cassa netto:
$-113.02M
1 W Prestazione:
-2.70%
1M Prestazione:
-34.55%
6M Prestazione:
-80.11%
1 anno Prestazione:
-86.23%
Intervallo 1D:
$1.41
$1.52
Intervallo di 1 settimana:
$1.2905
$1.52
Portata 52W:
$1.2905
$13.07
Biomea Fusion Inc Stock (BMEA) Company Profile
Nome
Biomea Fusion Inc
Settore
Industria
Telefono
(650) 980-9099
Indirizzo
900 MIDDLEFIELD ROAD, REDWOOD CITY
Confronta BMEA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
1.44 | 55.61M | 0 | -144.01M | -113.02M | -4.01 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-09 | Iniziato | Edward Jones | Buy |
| 2024-09-27 | Aggiornamento | Rodman & Renshaw | Neutral → Buy |
| 2024-09-27 | Aggiornamento | Truist | Hold → Buy |
| 2024-08-29 | Iniziato | CapitalOne | Overweight |
| 2024-06-11 | Downgrade | Truist | Buy → Hold |
| 2024-06-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-04-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-02-06 | Iniziato | Truist | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-06-26 | Downgrade | Jefferies | Buy → Hold |
| 2023-05-12 | Iniziato | Barclays | Overweight |
| 2023-03-29 | Reiterato | Oppenheimer | Outperform |
| 2023-03-28 | Reiterato | H.C. Wainwright | Buy |
| 2023-02-24 | Iniziato | Citigroup | Buy |
| 2022-06-02 | Ripresa | H.C. Wainwright | Buy |
| 2022-01-12 | Iniziato | H.C. Wainwright | Buy |
| 2021-12-17 | Iniziato | Oppenheimer | Outperform |
| 2021-05-11 | Iniziato | JP Morgan | Overweight |
| 2021-05-11 | Iniziato | Jefferies | Buy |
| 2021-05-11 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Biomea Fusion Inc Borsa (BMEA) Ultime notizie
Northern Trust Corp Boosts Holdings in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
D. E. Shaw & Co. Inc. Acquires New Shares in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Biomea Fusion stock hits 52-week low at $1.37 amid sharp decline - Investing.com India
Biomea Fusion (NASDAQ:BMEA) Earns “Buy” Rating from D. Boral Capital - Defense World
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Average Recommendation of “Buy” by Analysts - Defense World
Biomea Fusion Focuses on Core Programs in Q1 2025 - TipRanks
Analyst Maintains Buy Rating on Biomea Fusion (BMEA) with $16 Pr - GuruFocus
Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia - The Manila Times
Biomea Fusion’s BMF-500 Selected for Poster Presentation at - GlobeNewswire
Biomea Fusion’s BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia - Nasdaq
Breakthrough Leukemia Drug BMF-500 Exceeds Survival Expectations in Hard-to-Treat Patients - Stock Titan
Barclays PLC Increases Holdings in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
HC Wainwright Issues Pessimistic Forecast for Biomea Fusion (NASDAQ:BMEA) Stock Price - Defense World
Biomea Fusion's Stock Plummets After Price Target Cut — Bearish Retail Traders Speculate Next Moves - NewsBreak: Local News & Alerts
Biomea Fusion stock target cut to $18 by H.C. Wainwright - Investing.com Nigeria
BMEA: HC Wainwright & Co. Adjusts Price Target for Biomea Fusion - GuruFocus
Biomea Fusion (BMEA) Receives Buy Rating from D. Boral Capital | - GuruFocus
Biomea Fusion (BMEA) Receives Buy Rating from D. Boral Capital | BMEA Stock News - GuruFocus
Biomea Fusion (BMEA) Price Target Reduced by H.C. Wainwright | B - GuruFocus
Biomea Fusion reports Q1 EPS (80c), consensus (60c) - TipRanks
Biomea Fusion (BMEA) Focuses on Strategic Growth and Pipeline Ad - GuruFocus
Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights - The Manila Times
Biomea Fusion, Inc. Implements Strategic Realignment to Focus on Core Diabetes Programs and Optimize Cash Runway - Nasdaq
Biomea Fusion Slashes Workforce by 35%, Shifts Focus to $200B Diabetes Market Opportunity - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Biomea Fusion (BMEA) Projected to Post Earnings on Thursday - Defense World
Biomea Fusion, Inc. (NASDAQ:BMEA) Shares Sold by Alliancebernstein L.P. - Defense World
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Rating of “Buy” from Analysts - Defense World
Wellington Management Group LLP Invests $317,000 in Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Reviewing Biomea Fusion (NASDAQ:BMEA) and Tango Therapeutics (NASDAQ:TNGX) - Defense World
Biomea Fusion’s SWOT analysis: diabetes drug progress lifts stock outlook By Investing.com - Investing.com Australia
Biomea Fusion's SWOT analysis: diabetes drug progress lifts stock outlook - Investing.com
Biomea Fusion stock hits 52-week low at $1.86 amid sharp decline - Investing.com Canada
IVEY PMI Reading Due Next Week in Canada - The Globe and Mail
Biomea Fusion stock hits 52-week low at $1.86 amid sharp decline By Investing.com - Investing.com South Africa
Biomea Fusion Inc Azioni (BMEA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):